Investments
45Portfolio Exits
1About Sunland Capital
Sunland Capital (山蓝资本) is focused on early-stage investments in the medical & healthcare industry, with a particular interest in biomedical, medical devices (e.g. in vitro diagnostic and genetic technology, minimally invasive intervention, implantation, minimally invasive surgical instruments, medical robots, etc.), medical services, and other high-growth segments.
Want to inform investors similar to Sunland Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Sunland Capital News
Feb 25, 2021
WuXi Diagnostic Investment (Cayman) Limited, a Shangai, China-based diagnostics company, completed US$150m in series B funding Backers also included new investors Thermo Fisher Scientific Inc., Shiyu Capital, ABC International Holdings Limited, Sunland Capital and CCBI Tech Venture The company also intends to use the funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline WuXi Diagnostics also focuses on integrated diagnostics via an open-access innovation enabling platform, centered on multi-omics clinical data from multidisciplinary technologies WXDX is establishing an open-access enabling platform, with multidisciplinary technologies, clinical big data and algorithms to continuously launch innovative diagnostic services The company has its headquarters and a CAP-accredited Independent Clinical Laboratory in Shanghai Tags:
Sunland Capital Investments
45 Investments
Sunland Capital has made 45 investments. Their latest investment was in Hexin Medical as part of their Series A on March 3, 2023.
Sunland Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/2/2023 | Series A | Hexin Medical | Yes | 3 | ||
1/24/2023 | Series B | Meihua Yiliao | Yes | 1 | ||
1/12/2023 | Seed VC | Forethought | Yes | 2 | ||
1/3/2023 | Series C | |||||
9/30/2022 | Series A - II |
Date | 3/2/2023 | 1/24/2023 | 1/12/2023 | 1/3/2023 | 9/30/2022 |
|---|---|---|---|---|---|
Round | Series A | Series B | Seed VC | Series C | Series A - II |
Company | Hexin Medical | Meihua Yiliao | Forethought | ||
Amount | |||||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 3 | 1 | 2 |
Sunland Capital Portfolio Exits
1 Portfolio Exit
Sunland Capital has 1 portfolio exit. Their latest portfolio exit was Prime Gene Therapeutics on December 07, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/7/2022 | IPO | Public | 1 |
Date | 12/7/2022 |
|---|---|
Exit | IPO |
Companies | |
Valuation | |
Acquirer | Public |
Sources | 1 |
Sunland Capital Team
1 Team Member
Sunland Capital has 1 team member, including current Chief Executive Officer, Daozhi Liu.
Name | Work History | Title | Status |
|---|---|---|---|
Daozhi Liu | Chief Executive Officer | Current |
Name | Daozhi Liu |
|---|---|
Work History | |
Title | Chief Executive Officer |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.